Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/0005—Vertebrate antigens
  • A61K39/0007—Nervous system antigens; Prions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
  • A61K2039/53—DNA (RNA) vaccination
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
  • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
  • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
  • A61K2039/6031—Proteins
  • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
  • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Definitions

• the disclosure relates to the technical fields of immunology and medicine, and in particular to the treatment of Alzheimer’s disease and other diseases of protein misfolding.
• AD Alzheimer’s disease
• senile dementia a progressive disease resulting in senile dementia.
• the disease falls into two categories: late onset, which occurs in old age (65+yeai'S) and early onset, which develops well before the senile period, i.e., between 35 and 60 years.
• late onset which occurs in old age (65+yeai'S)
• early onset which develops well before the senile period, i.e., between 35 and 60 years.
• the pathology is the same but the abnormalities tend to be more severe and widespread in cases beginning at an earlier age.
• the disease is characterized by at least two types of lesions in the brain, neurofibrillary tangles and senile plaques.
• Senile plaques i.e., amyloid plaques
• senile plaques are areas of disorganized neuropil up to 150 ⁇ m across with extracellular amyloid deposits at the center which are visible by microscopic analysis of sections of brain tissue.
• the accumulation of amyloid plaques within the central nervous system is also associated with Down's syndrome and other cognitive disorders. Cerebral amyloid angiopathy (CAA), and the ocular disease Age-Related Macular Degeneration,
• a principal constituent of the plaques is a peptide termed A ⁇ or ⁇ -amyloid peptide.
• a ⁇ peptide is a 4-kDa internal fragment, of 38-43 amino acids of a larger transmembrane glycoprotein named amyloid precursor protein (APP).
• APP amyloid precursor protein
• a ⁇ is primarily found in both a short form, 40 amino acids in length, and a long form, ranging from 42-43 amino acids in length.
• Part of the hydrophobic transmembrane domain of APP is found at the carboxy end of A ⁇ , and may account for the ability of A[) to aggregate into plaques, particularly in the case of the long form. Accumulation of amyloid plaques in the brain eventually leads to neuronal cell death.
• the cognitive and physical symptoms associated with this type of neural deterioration characterize Alzheimer’s disease.
• disclosure is directed to one or more peptides comprising 3-10 amino acids from residues 1 ⁇ 10 or residues 12-25 of SEQ ID NO.01 .
• the peptide may include an amino acid sequence selected from the group consisting of any one of SEQ ID NO:02 to SEQ ID NO:96.
• the peptide is from residues 1-7 of SEQ ID NO’.Ol and optionally a C-tenninal cysteine and, as an example, include any one of SEQ ID NO:05 to SEQ I D NO:09, SEQ ID NO: 13 to SEQ ID NO: 16, SEQ ID NO:20 to SEQ ID NO:22, SEQ ID NO;26, SEQ ID NO:27, or SEQ ID NO:3I.
• the disclosure is directed to a peptide from residues 2-8 of SEQ ID NO:01 and optionally a C- tenninal cysteine that for example, include any one of SEQ ID NO: 12 to SEQ ID NO: 16, SEQ ID NO: 19 to SEQ ID NO:22, SEQ ID NO:25 to SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:31 or SEQ ID NO:34.
• the disclosure is directed to a peptide from residues 12-24 or from residues 12-23 or from residues 12-22 or from residues 13-25 or from residues 13- 24 or from residues 13-23 or from residues 13-22 or from residues 14-25 or from residues 14-24 or from residues 14-23 or from residues 14-22 or from residues 15-25 or from residues 15-24 or front residues 15-23 or front residues 15-22 of SEQ ID NO:0 I .
• the peptide may include a C-terminal cysteine
• the disclosure is directed to a peptide of structure: [first peptide]-] linker l]-[second peptide]-[linker 2]-[Cys], where the first peptide and the second peptide are the same or different and include, e.g. , 3-10 amino acids from residues 1-10, 3-10 amino acids from residues 12-25 of SEQ ID NO :01 , SEQ ID NO;02 through SEQ ID NO:96, and like sequences with an -RR. dipeptide sequence appended to an end (e.g. t SEQ ID NO; 101).
• l inker 1 and linker 2 may be tire same OF different
• the peptide may include a linker, for example to a carrier, at a C-terminal portion of the peptide, which may include an amino acid sequence of AA, AAA, KK, K.KK, SS, SSS, AGAG (SEQ ID NO;99), GG, GGG, GAGA(SEQ ID NO;98) and KGKG (SEQ ID NO; 100).
• the linker to the carrier if present, may include a C- terrn.inai cysteine (C).
• the polypeptide may include the amino acid sequence of DAEFRIID-XXC (SEQ ID NO; 05) or DAEFRHDRR-XXC (SEQ ID NO;101), wherein XX and C are independently optional and, if present, XX can be AA, AAA , KK, K.KK, SS, SSS AGAG (SEQ ID NO;99), GG, GGG, GAGA (SEQ ID NO:98) and KGKG (SEQ ID NO; 100) .
• the peptide further comprises a blocked amine at the N-terniiiius .
• the disclosure is directed to an immunotherapy composition including the polypeptides of the disclosure, wherein the polypeptide may be linked to a carrier.
• the carrier may include serum albumins, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid (IT), diphtheria toxoid (DI ), a genetically modified cross-reacting material (CRM) of diphtheria toxin, CRM 197, meningococcal outer membrane protein complex (OMPC) and H. influenzae protein D (HiD), rEPA (Pseudomonas aeruginosa exotoxin A), KLH (keyhole limpet hemocyanin), and flagellin.
• the disclosure are directed to a pharmaceutical composition that includes the polypeptides and/or the immunotherapy compositions of the disclosure, and including at least one adjuvant.
• the adjuvant may be aluminum hydroxide, aluminum phosphate, aluminum sulfate, 3 De-O-acylated monophosphoryl lipid A (MPL) and synthetic analogs thereof, QS-21, QS-I8, QS-17, QS-7, TQL1055, Complete Freund's Adjuvant (CEA), Incomplete Freund's Adjuvant (IF A), oil in water emulsions (such as squalene or peanut oil), CpG, polyglutamic acid, polylysine, AddaVaxTM, MF59 ®, and combinations thereof.
• the formulation may include one or more of a liposomal formulation, a diluent, or a multiple antigen presenting system (MAP).
• MAP may include one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic moieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen- presenting platforms and gold nanoparticles.
• Embodiments of the disclosure are also directed to nucleic acid sequences encoding the polypeptides and the immunotherapy compositions of the disclosure.
• the nucleic acids may be included in a nucleic acid immunotherapy composition including the nucleic acid and at least one adjuvant.
• the disclosure is directed to a methods for treating oreffecting prophylaxis of Alzheimer’s disease in a subject, and methods for inhibiting or reducing aggregation of A ⁇ in a subject having or at risk of developing Alzheimer’s disease.
• the methods include administrating to the subject an immunotherapy composition, a nucleic acids immunotherapy composi t ion, or a pharmaceutical formulation of the disclosure.
• the methods of the disclosure may include repeating the administering at least a second time, at least a third time, at least a fourth time, at least a fifth time, or at least a sixth time, and may include repeating the administerin g at an interval of about bimonthly, of about 21 to about 28 days, of about quarterly, of about biannually, or of about annually.
• methods of the disclosure are directed to inducing an immune response in an animal.
• the methods include administering to the anima! a polypeptide, an immunotherapy composition, a pharmaceutical formulation or a nucleic acid immunotherapy composition of the disclosure in a regimen effective to generate an immune response including antibodies that specifically bind to A ⁇ .
• the immune response may include antibodies that specifically bind to the N-terminal region of A ⁇ .
• the disclosure is directed to an immunization kit including an immunotherapy composition of the disclosure and may include an adjuvant, wherein the immunotherapy composition may be in a fest container and the adjuvant may be a second container.
• the disclosure is di rected to a kit including a nucleic acid immunotherapy composition of the disclosure and may include an adjuvant
• the nucleic acid may be in a first container and the adjuvant may be in a second container.
• FIG, 1 shows the results of an experiment comparing the titers of Guinea pig serum for amyloid beta single peptide immunogens QKLVFFAEC (SEQ ID NO: 40) and DAEFRHDC (SEQ ID NO:39). All immunogens comprised a C-termiual cysteine for coupling to maleimide activated CRM197 carrier. QS21 was utilized as an adjuvant in AddaVax squalene-based oil-in-water nano-emulsion.
• FIG, 2 shows the results of an experiment measuring the titer of murine serum for amyloid beta single peptide immunogen AEFRHDSGC (SEQ ID NO138) and DAEFR.HDC (SEQ ID NO39).
• the peptides were coupled to maleimide activated CRM 197 carrier through the N-terminal cysteine.
• QS21 was used as an adjuvant.
• the disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (A ⁇ ) peptide.
• the disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing and preventing formation of deposits, inhibiting or reducing aggregation of A ⁇ , blocking the binding and/or uptake of A ⁇ by neurons, inhibiting transmission of A ⁇ species between ceils, and inhibiting propagation of pathology between brain regions in a subject having or at risk of developing Alzheimer’s disease or other diseases containing amyloid-beta accumulations.
• the methods include administering to such patients the compositions comprising an amyloid-beta (A ⁇ ) peptide.
• the term “about” encompassesinsubstantial variations, such as values within a standard margin of error of measurement (e.g., SE.M) of a stated value.
• SE.M standard margin of error of measurement
• the term “about” as used herein when referring to a measurable value such as a parameter, an amount, a temporal duration can encompass variations of +/-10% or less, +/-5% or less, or +/-!% or less or less of and from the specified value.
• Designation of a range of values includes all integers within or defining the range, and all subranges defined by integers within the range. As used herein, statistical significance means p ⁇ 0,05.
• compositions or methods “comprising” or “including” one or more recited elements may include other elements not specifically recited.
• a composition that “comprises” or “includes” a polypeptide sequence may contain the sequence alone or in combination with other sequences or ingredients.
• An individual is at increased risk of a disease if the subject has at least one known risk-factor (e.g. , age, genetic, biochemical, family history, and situational exposure) placing individuals with that risk factor at a statistically significant greater risk of developing the disease than individuals without the risk factor.
• risk-factor e.g. , age, genetic, biochemical, family history, and situational exposure
• patient includes human and other mammalian subjects that recei ve either prophylactic or therapeutic treatment, including treatment naive subjects.
• subject or patient refer to any single subject for which treatment is desired, including other mammalian subjects such as, humans, cattle, dogs, guinea pigs, rabbits, and so on. Also intended to be included as a subject are any subjects involved in clinical research trials not showing any clinical sign of disease, or subjects involved in epidemiological studies, or subjects used as controls.
• disease refers to any abnormal condition that impairs physiological function.
• the term is used broadly to encompass any disorder, illness, abnonnality, pathology, sickness, condition, or sy ndrome in which physiological function is impaired, irrespective of the nature of the etiology.
• symptom refers to a subjective evidence of a disease, such as altered gait, as perceived by the subject.
• signal refers to objective evidence of a disease as observed by a physician.
• the terms “treat” and “treatment” refer to the alleviation or ameli oration of one or more symptoms or effects associated w ith the disease, prevention, inhibition or delay of the onset of one or more symptoms or effects of the disease, lessening of the severity or frequency of one or more symptoms or effects of the disease, and/or increasing or trending toward desired outcomes as described herein.
• prevention refers to contacting (for example, administering) the peptide(s) or immunotherapy compositions of the present disclosure with a subject before the onset of a disease, with or without A ⁇ pathology already present (primary and secondary prevention), thereby delaying the onset of clinical symptoms and/or alleviating symptoms of the disease after the onset of the disease, compared to when the subject is not contacted with the peptide or immunotherapy compositions, and does not refer to completely suppressing the onset of the disease.
• prevention may occur for limited time after administration of the peptide or immunotherapy compositions of the present disclosure. In other cases, prevention may occur for the duration of a treatment regimen comprising administering the peptide or immunotherapy compositions of the present disclosure.
• reduction refers to decreasing the amount of A ⁇ and/or tan present in a subject or in tissue of the subject, or suppressing an increase in the amount of A ⁇ present in a subject or tissue in a subject, which encompasses decreasing or suppressing an increase in (e .g., decreasing the rate of increase) the amount of A ⁇ present, accumulated, aggregated, or deposited in the subject or tissue in the subject.
• the decrease in or suppression of an increase in (e.g, decreasing the rate of increase) the amount of A ⁇ present, accumulated, aggregated, or deposited in the subject refers to an amount of A ⁇ present, accumulated, aggregated, or deposited in.
• the decrease in or suppression, of an increase in (e.g. , decreasing the rate of increase) the amount of A ⁇ present, accumulated, aggregated, or deposited in the subject refers to an amount of A. ⁇ present, accumulated, aggregated, or deposited in the periphery (e.g., peripheral circulatory system) of the subject.
• the decrease in or suppression of an increase in (e.g., decreasing the rate of increase) the amount of A ⁇ present, accumulated, aggregated, or deposited in the subject refers to an amount of A ⁇ present, accumulated, aggregated, or deposited in the brain of the subject
• the A ⁇ reduced is the pathological form(s) of the A ⁇ (e.g. extracellular plaque deposits of the ⁇ » aniyloid peptide (A ⁇ ); neuritic amyloid plaques).
• pathological indicators of neurodegenerative disease and/or ⁇ amyloidopathies are decreased.
• epitope of “antigenic determinant” refers to a site on an antigen to which B and/or T cells respond, or to a site on an antigen to which an antibody binds.
• Epitopes can be formed both from contiguous ammo acids or from noncontiguous ammo acids juxtaposed by tertiary folding of a protein. Epitopes formed from contiguous amino acids are typically retained on exposure to denaturing solvents whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
• An epitope typically includes at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 amino acids in a unique spatial conformation.
• Methods of determining spatial conformation of epitopes include, for example, x-ray crystallography and 2 -dimensional nuclear magnetic resonance. See, e.g. , Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E, Morris, Ed. (1996).
• an “immunogenic agent” or “immunogen” or “antigen” is capable of inducing an immunological response against itsel f or moddred/processed versi ons of itself upon administration to an animal, optionally in conjunction with an adjuvant.
• the terms “immunogenic agent” or “immunogen” or “antigen” refer to a compound or composition comprising a peptide, polypeptide or protein which is “antigenic” or “immunogenic” when administered in an appropriate amount (an “immunogenically effective amount”), i.e., capable of inducing, eliciting, augmenting or boosting a cellular and/or humoral immune response and of being recognized by the products of that response (T cells, antibodies).
• An immunogen can be a peptide, or a combination of two or more peptides, that includes at least 3, at least 4, at least 5, at least 6. at least 7, at least 8. at least 9, or at least 10 amino acids in a liner or spatial conformation.
• An immunogen may be effective when given alone or hi combination, or linked, to, or fused to, another substance (which can be administered at one time or over several intervals).
• An immunogenic agent or immunogen may include an antigenic peptide or polypeptide that is linked to a carrier as described herein.
• a nucleic acid such as DNA or RNA that encodes an antigenic peptide or polypeptide is referred to as a "DNA [or RNA] immunogen," as the encoded polypeptide is expressed in vivo after administration of the DNA or RNA.
• the peptide or polypeptide can be recombinantly expressed from a vaccine vector, which can be naked DNA or RNA that comprises the peptide or polypeptide coding sequence operably l inked to a promoter, e.g., an expression vector or cassette as described herein.
• adjuvant refers to a compound that, when administered in conjunction with an antigen, augments the immune response to the antigen, but when administered alone does not generate an immune response to die antigen.
• adjuvants can augment an immune response by several mechanisms including lymphocyte recruitment, stimulation of B and/or T cells, and stimulation of macrophages.
• An adjuvant may be a natural compound, a modified version of or deri vative of a natural compound, or a synthetic compound.
• peptide and “polypeptide” are used interchangeably herein and refer to a chain of two or more consecutive amino acids. If and when a distinction is made, context makes the meaning clear. For example, if two or more peptides described herein are joined to make a dimeric or multimeric peptide, polypeptide may be used to indicate “poly” or “more than one” peptide.
• pharmaceutically acceptable means that the carrier, diluent, excipient, adjuvant, or auxiliary is compa tible with the other ingredients of a pharmaceutical formulation and not substantially deleterious to the recipient thereof.
• immunotherapy refers to the development of a beneficial humoral (antibody mediated) and/or a cellular (mediated by antigen-specific T cells or their secretion products) response directed against an A ⁇ peptide in a recipient.
• a response can be an active response induced by administration of immunogen (e.g. an A ⁇ peptide).
• a cellular immune response is elicited by the presentation of polypeptide epitopes in association with Class I or Class II MHC molecules to activate antigen-specific CD4 : T helper cells and/or CD8 + cytotoxic T ceils. The response may also involve activation of monocytes, macrophages, NK.
• the presence of a cell-mediated immunological response can be determined by proliferation, assays (CD4 + T cells) or CTL (cytotoxic T lymphocyte) assays.
• the relative contributions of humoral and cellular responses to the protective or therapeutic effect of an immunogen can be distinguished by separately isolating antibodies and T-cells from an immunized syngeneic animal and measuring protective or therapeutic effect in a second subject.
• Amyloid Beta (A ⁇ ) A ⁇
• a ⁇ (also referred to herein as beta amyloid peptide or Abeta) peptide is about a 4- kDa internal fragment of 38-43 amino acids of APP ( A ⁇ 39, A ⁇ 40, A ⁇ J41, A ⁇ 42, and A ⁇ 43).
• a ⁇ 40 for example, consists of residues 672-711 ofAPP and A ⁇ 42 consists of residues 673-713 of APP.
• a ⁇ is found in both a "short form”, 40 amino acids in length, and a "long form", ranging from 42-43 amino acids in length.
• Epitopes or antigenic detenninants are located within the N-termmus of the A ⁇ peptide and include residues within amino acids 1-10 of A ⁇ , for example from residues 1-3, 1-4, 1-5, 1-6, 1-7, or 3-7 of A ⁇ J42. Additional examples of epitopes or antigenic detenninants include residues 2-4, 2-5, 2-6, 2-7, or 2-8 of A ⁇ , residues 3-5, 3-6, 3-7, 3-8, or 3-9 of A ⁇ , or residues 4-7, 4-8, 4-9, or 4-10 of A ⁇ 42.
• Epitopes or antigenic detenninants are also located in a central region of the A ⁇ peptide and include residues within amino acid residues 12-25, within residues 12-24, within residues 12-23, within residues 12-22, within residues 13-25, within residues 13-24, within residues 13-23, within residues 13-22, within residues 14-25, within residues 14-24, within residues 14-23, within residues 14-22, within residues 15-25, within residues 15-24, within residues 15-23, or within residues 15-22 of A ⁇ , For example, from residues 12-17, 12-18, 12-19, 12-20, 12-21, 13-
• epitopes or antigenic determinants include residues 18-20, 18-21 , 18-22, 18-23, 18-24, 18-25, 19-21, 19-22, 19-23, 19-24, 19-25, 20-22, 20-23, 20-24, 20-25, 21-23, 21-24 or 21-25 of A ⁇ 42.
• a ⁇ is the principal component of characteristic plaques of Alzheimer’s disease. A ⁇ is generated by processing of a l arger protein APP by two enzymes, termed beta and gamma secretases. Known mutations in APP associated with Alzheimer's disease occur proximate to the site of beta or gamma secretase, or within A ⁇ .
• Part of the hydrophobic transmembrane domain of APP is found at the carboxy end of A ⁇ , and may account for the ability of A ⁇ to aggregate into plaques, particularly in the case of the long form. Accumula tion of amyloid plaques in the brain eventually leads to neuronal cell death. The physical symptoms associated with this type of neural deterioration characterize Alzheimer's disease.
• Agent used for active immunization can induce in a patient an immune response and can serve as an immunotherapy.
• Agents used for acti ve immunization can be, for example, the same types of immunogens used for generating monoclonal antibodies in laboratory animals, and may include 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 or more contiguous amino acids from a region of A ⁇ peptide.
• the immunogen can include an A ⁇ peptide comprising 3-10 amino acids from residues 1-10 of the N-terminal sequence of A ⁇ (SEQ ID NO:01 ). In some embodiments of the disclosure, the immunogen can include an A ⁇ peptide comprising 3-10 amino acids from residues 12-25 of A ⁇ (SEQ ID NO:01). In some embodiments, the peptide is unphosphorylated. In some embodiments, the peptide is phosphorylated at serine (S), threonine (T), and/or tyrosine (Y) phosphorylation sites. In each of the embodiments of the peptide described herein, the peptide may comprise, consist, or consist essentially of the recited sequences.
• the A ⁇ peptide immunogen can include 3-10 amino acids from residues 1-10 or residues 12-25 of DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO:01 ).
• the A ⁇ peptide includes the following:
• the A ⁇ peptide is DAEFRHD (SEQ ID NO:05), AEFRHDS (SEQ ID NO: 12), or EFRHDSG (SEQ ID NO: 18).
• Each A ⁇ sequence optionally further comprises a C ⁇ terminal cysteine like, for example, AEFRHDSGC (SEQ ID NO:38), DAEFRHDC (SEQ ID NO:39) and QKLVFFAEC (SEQ ID NO:40).
• the peptide may comprise, consist, or consist essentially of the recited sequences
• the A ⁇ peptide according to SEQ ID NO: 1 through SEQ ID NO:96 further includes an arginine-arginine dipeptide (R.R) at the N-terminal, the C-terminal or both terminii .
• R.R arginine-arginine dipeptide
• SEQ ID NO: 101 DAEFRHD (SEQ ID NO:05) with an ⁇ RR dipeptide at the C-terminus.
• the immunogen as described herein further comprises a linker (for example, to a carrier) at a C-terminal portion or N-terminal portion of the polypeptide.
• the linker comprises an amino acid sequence including AA, AAA, KK, KKK, SS, SSS, AGAG (SEQ ID NO:99), GG, GGG, GAGA (SEQ ID NO:98), and KGKG (SEQ ID NO: 100),
• the peptide further comprises a C-terminal cysteine, and some embodiments that comprise a linker further comprise a C-terminal cysteine on the C- terminal end of the linker.
• the peptide further comprises a N-terminal cysteine
• some embodiments that comprise a linker further comprise a N-terminal cysteine on the N-terminal end of the linker.
• the immunogen peptides further comprise a blocked amine at the N-tenninus.
• the two or more A ⁇ peptides are linked to form an A ⁇ polypeptide.
• the one or more A ⁇ peptides can be linked by an intra-peptide linker(s), which linker is as described above and herein.
• a polypeptide linker located between the C- terniinai of the first peptide and the N terminal of the second peptide.
• the A ⁇ polypeptide may be arranged in any order.
• a specific A ⁇ pepti de (“A ⁇ I”) may be positioned at the N-terminal portion of a dual A ⁇ polypeptide and the same or a different A ⁇ peptide (for this example, a different A ⁇ , “A ⁇ 2”) may be positioned at the C-terminal portion of the dual polypeptide.
• the A ⁇ peptides in this example could be arranged, in the opposite orientation. (A ⁇ 2 N-terminal to A ⁇ 1 ), Reference to a first peptide or a second peptide herei n is not intended to suggest an order of the A ⁇ peptides in embodiments that comprise more than one A ⁇ peptide of the immunogens.
• the either the N-terminal or C-terminal portion of the A ⁇ peptide or A ⁇ polypeptide can include a linker for conjugating the peptides or the polypeptide to a carrier, which linker is as described above and herein.
• the A ⁇ peptide or polypeptide that comprise a linker further comprise a C-terminal cysteine on the C-terminal or N-terminal end of the linker .
• the immunogen peptides further comprise a blocked amine at the N-terminus.
• any of the A ⁇ peptides or polypeptides may include a C-terminal cysteine without the linker.
• the linker may be a cleavable linker.
• cleavable linker refers to any linker between the antigenic peptides that promotes or otherwise renders the A ⁇ polypeptide more susceptible to separation from each other by cleavage (for example, by endopeptidases, proteases, low pH or any other means that may occur within or around the antigen-presenting cell) and, thereby, processing by the antigen-presenting cell, than equivalent peptides lacking such a cleavable linker.
• the cleavable linker is a protease-sensitive dipeptide or oligopeptide cleavable linker. In certain embodiments, the cleavable linker is sensitive to cleavage by a protease of the trypsin family of proteases.
• the cleavable linker comprises an amino acid sequence including arginiae-arginine (Arg-Arg), arginine- arginine-valine-arginine ( Arg -Val -Arg- Arg; SEQ ID NO :97), Gly-Ala-GIy-Ala (SEQ ID NO:98), Ala-Gly-Ala-Gly (SEQ ID NO:99), Lys-Gly-Lys-Gly (SEQ ID NO: 100), valine- citrulline (Val-Cit), valine-arginine (Val-Arg), valine-lysine (Val-Lys), valine-alanine (Vai-Ala), and phenylalaiiine-lysine (Phe-Lys),
• the cleavable linker is arginine- arginine (Arg- Arg) .
• the linker comprises between about 1-10 amino acids, about 1-9 amino acids, about 1-8 amino acids, about 1-7 amino acids, about 1-6 amino acids, about 1-5 amino acids, about 1-4 amino acids, about 1-3 amino acids, about 2 amino acids or one (1) amino acid.
• the linker is one amino acid, two amino acids, three amino acids, four amino acids, five amino acids, six amino acids, seven amino acids, eight amino acids, nine amino acids, or ten amino acids.
• the amino acid composition of a linker can mimic the composition of linkers found in natural multidomain proteins, where certain amino acids are overrepresented, underrepresented or equi-represented in natural linkers as compared to their abundance in whole protein.
• threonine (Thr) serine (Ser), proline (Pro)
• Gly aspartic acid
• Asp lysine
• Gin glutamine
• Asparagine Asn
• arginine Arg
• Phe phenylalanine
• glutamic acid (Glu) and alanine (Ala) are overrepresented in natural linkers.
• isoleucine Ile
• tyrosine Tr
• Trp tryptophan
• cysteine Cys
• Ile isoleucine
• Trp tyrosine
• Trp tryptophan
• cysteine Cys
• Ile isoleucine
• Trp tyrosine
• Trp tryptophan
• cysteine Cys
• overrepresented amino acids were polar uncharged or charged residues, which constitute approximately 50% of naturally encoded amino acids
• Pro, Thr, and Gin were the most preferable amino acids for natural linkers. See, e.g., Chen, X. et al., “Fusion Protein Linkers: Property, Design and Functionality” Adv Drug Deliv Rev., 15; 65(10): 1357-1369 (2013).
• the amino acid composition of a linker can mimic the composition of linkers commonly found in recombinant proteins, which can generally by classified as flexible or rigid linkers.
• flexible linkers found in recombinant proteins are generally composed of small, non-polar (e,g. Gly) or polar (e.g. Ser or Thr) amino acids whose small size provides flexibility and allows for mobility of the connecting functional domains.
• the incorporation of, e.g., Ser or Thr can maintain the stability of the linker in aqueous solutions by forming hydrogen bonds with the water molecules, and therefore can reduce interactions between the linker and the immunogens.
• a linker comprises stretches of Gly and Ser residues (“GS” linker).
• linkers can be rich in small or polar amino acids such as Gly and Ser but also contain additional amino acids such as Thr and Ala to maintain flexibility, as well as polar amino acids such as Lys and GIu to improve solubility. See, e.g,, Chen, X. et al.. Adv Drug Deliv Rev., 1.5; 65(10): 1357-1369 (2013).
• the A ⁇ polypeptide comprises, consists essentially of or consists of an amino acid sequence selected from DAEFRHD (SEQ ID NO:05), DAEFRHDRR (SEQ ID NO: 101), EFRHDSG (SEQ ID NO: 18), AEFRHDS (SEQ ID NO: 12), or QKLVFFAE (SEQ ID NO:61) wherein.
• XX is optionally appendedto the C-terminal end of SEQ ID NOS:05, 101 , 12, or 18, and a cysteine is optionally appended to the C-terminal end of SEQ ID NOS:05, 101, 12, or 18, or if XX is present, to the C-terminal end of the XX.
• XX can be the same or different amino acids and in some embodiments are A A, AAA, KK, KK.K, SS, SSS, , GG and GGG. In addition, XX may represent AGAG (SEQ ID NO:99), GAGA (SEQ ID NO:98), and KGKG (SEQ ID NO: 100).
• the dual A ⁇ polypeptide is as follows, from N-terminal to C-terminal:
• both the first peptide and the second peptide are from residues 1-10 of SEQ ID NO:01, and may be the same or different.
• both of the first peptide or the second peptide are from residues 12-25 of SEQ ID NO10.1 , and may be the same or different.
• either the first or the second peptide is from residues I- 10 of SEQ ID NO:01 and the other peptide is from residues 12-25 of SEQ ID NO:01.
• linker I and linker 2 may be the same or different.
• At least one of the first peptide or the second peptide is selected from SEQ ID NO:02 through SEQ ID NO:39, and in some embodiments, both the first peptide and the second peptide are selected from SEQ ID NO.02 through SEQ ID NO: 39.
• at least one of the first pepti de or the second peptide is selected from SEQ ID NO:40 through SEQ ID NO:96, and in some embodiments, both the first peptide and the second peptide are selected from SEQ ID NO:40 through SEQ ID NO:96.
• either the first or the second peptide is selected from SEQ ID NO:02 through SEQ ID NO:39 and SEQ ID NO: 101, and the other peptide is selected from SEQ ID NO:40 through SEQ ID NO:96 and SEQ ID NO.101 .
• either the first peptide or the second peptide includes a peptide according to SEQ ID NO:02 through SEQ ID NO:96 further comprising an RR- or -RR at the N-terniinal or C-terminal end, respectively.
• both the first and the second peptide includes a peptide according to SEQ ID NO:02 through SEQ ID NO',96 further comprising an RR- or -RR dipeptide at the N-terminal or C-terminal end, respectively.
• the -RR dipeptide is on the C ⁇ terminus.
• each of the first peptide and the second peptide include residues 1-10 of SEQ ID NO:01 , or residues 12-25 of SEQ ID NO:0L or one of SEQ ID NO:02 through SEQ ID NO:96, or SEQ ID NO: 101, or a peptide according to SEQ ID NO.02 through SEQ ID NO:96 further comprising an RR- or -RR at the N-terminal or C-terminal end, respectively.
• Non-limiting examples of the A ⁇ peptides include SEQ ID NO:02 to SEQ ID NO.96, and like sequences further including a C-terminal cysteine or C-terminal -RR dipeptide, for example SEQ ID NO: 101.
• Peptide-Carrier Immunogens include SEQ ID NO:02 to SEQ ID NO.96, and like sequences further including a C-terminal cysteine or C-terminal -RR dipeptide, for example SEQ ID NO: 101.
• a ⁇ peptides are immunogens in accordance with the disclosure.
• the peptides described herein can be linked to a suitable carrier to help elicit an immune response.
• one or more the peptides and polypeptides of the disclosure can be linked to a carrier.
• the A ⁇ peptide may be linked to the carrier with or without a linker as described above and herein and, optionally, a C- terminal cysteine at C-terminal end of the linker and, if a linker is absent, at the C-terminal end of the peptide.
• each A ⁇ peptide or polypeptide may be linked to the carrier with or without spacer amino acids (e.g;, Gly-Gly, Gly-Gly-Gly, Ala-Ala, Ala-Ala-Ala, Lys-Lys, Lys- Lys-Lys, Ser-Ser, Ser-Ser-Ser, Gly-AIa-Gly-Ala (SEQ ID NO:98), Ala-Gly-Ala-Gly (SEQ ID NO:99), or Lys-Gly-Lys-Gly (SEQ ID NO: 100)) and optionally, a C-terminal cysteine or N- terminai cysteine to provide a linker between the peptide(s) and the carrier.
• spacer amino acids e.g;, Gly-Gly, Gly-Gly-Gly, Ala-Ala, Ala-Ala-Ala, Lys-Lys, Lys-Lys, Ser-Ser, Ser-Ser
• Suitable earners include, but are not limited to serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, or a toxoid from other pathogenic bacteria, such as diphtheria (e.g,, CRM 197 ), E. coli, cholera, or H. pylori, or an attenuated toxin derivative.
• T cell epitopes are also suitable carrier molecules.
• conjugates can be formed by linking peptide immunogens of the invention to an immunostimulatory polymer molecule (e,,g., tripalmitoyl-S -glycerine cysteine (Pam3Cys), mannan (a mannose polymer), or glucan (a ⁇ 1-2 polymer) ⁇ , cytokines (e.g., IL- 1 , IL-1 alpha and ⁇ peptides, IL-2, y-INF, IL-10, GM-CSF), and chemokines (e.g., MlP1- ⁇ and ⁇ , and RANTES), Additional carriers include virus-like particles.
• immunogenic peptides can also be linked to carriers by chemical crosslinking.
• Techniques for linking an immunogen to a carrier include the formation of disulfide linkages using N-succinimidyl-3 ⁇ (2 ⁇ pyridyl-thi- o)propionate (SPDP), and succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1 -carboxylate (SMCC) ( if the peptide lacks a sulfhydryl group, this can be provided by addition of a cysteine residue).
• SPDP N-succinimidyl-3 ⁇ (2 ⁇ pyridyl-thi- o)propionate
• SMCC succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1 -carboxylate
• chemical crosslinking can comprise use of SBAP (succinimidyl 3-(bromoacetamido)propionate), which is a short (6.2 angstrom) cross-linker for amine-to-sulfhydryl conjugation via N -hydroxysuccinimide (NHS) ester and bromoacety l reactive groups.
• SBAP succinimidyl 3-(bromoacetamido)propionate
• VLPs Virus-like particles
• pseudovirions represent subunit structures composed of multiple copies of a viral capsid and/or envelope protein capable of self-assembly into VLPs of defined spherical symmetry m vivo.
• peptide immunogens can be linked to at least one artificial T-cell epitope capable of binding a large proportion of MHC Class 11 molecules, such as the pan DR epitope ("PADRE").
• Pan DR-binding peptides PADRE are described in US 5,736,142, WO 95/07707, and Alexander, el al. Immunity, 1:751-761 (1994).
• Active immunogens can be presented in multimeric form in which multiple copies of an immunogen are presented on a carrier as a single covalent molecule.
• the carrier includes various forms of the A ⁇ pep tide.
• the A ⁇ pepti de of the immunogen can include peptides that have different A ⁇ antigens in different, orders, or may be present with or without an intrapeptide linker and/or a linker to a carrier.
• the immunogenic peptides can also be expressed as fusion proteins with carriers.
• the immunogenic peptides can be linked at the amino terminus, the carboxyl terminus, or internally to the carrier.
• the carrier is CRM 197.
• the carrier is diphtheria toxoid.
• the disclosure further provides nucleic acids encoding any of the amyloid-beta ( A ⁇ ) peptides as disclosed herein.
• the nucleic acid immunotherapy compositions as disclosed herein comprise, consist essentially of, or consist of a nucleic acid sequence encoding one or more amyloid-beta ( A ⁇ ) peptides as disclosed herein.
• the A ⁇ peptide includes a sequence that is 3-10 amino acid residues in length and from the first ten N-terminal residues of SEQ ID N0.01 or from residues 12-25 of SEQ ID NO:01 .
• one or more nucleic acids encoding any of SEQ ID NOS:2-96 and 101 provide an immunogen and a component of a pharmaceutical composition of the disclosure.
• one or more nucleic acids may encode any of SEQ ID NOS.2-96 with an RR- N-terminal or -RR C- terminal dipeptide.
• the peptide sequences may be encoded by the same or separate nucleic acid sequences that may also encode a linker to the carrier and an N- or C* terminal cysteine as described herein.
• the sequence may also encode a linker or cleavable linker as described herein.
• a nucleic acid such as DNA that encodes an immunogen and is used as a vaccine can be referred to as a "DNA immunogen” or “DNA vaccine” as the encoded polypeptides are expressed in vivo after administration of the DNA.
• DNA vaccines are intended to induce antibodies against the proteins of interest they encode in a subject by: integrating DNA encoding the proteins of interest into a vector (a plasmid or virus); administering the vector to the subject; and expressing the proteins of interest in the subject in which the vector has been administered to stimulate the immune system of the subject.
• a DNA vaccine remains in the body of the subject for a long time after the administration, and continues to slowly produce the encoded proteins. Thus, excessive immune responses can be avoided.
• DNA vaccines can also be modified using a genetic engineering techniques.
• such nucleic acids further encode a signal peptide and can be expressed with the signal peptide linked to peptide.
• Coding sequences of nucleic acids can be operably linked with regulatory sequences to ensure expression of the coding sequences, such as a promoter, enhancer, ribosome binding site, transcription termination signal, and the like.
• the nucleic acids encoding A ⁇ can occur hi isolated form or can be cloned into one or more vectors.
• the nucleic acids can be synthesized by, for example, solid state synthesis or PCR of overlapping oligonucleotides.
• Nucleic acids encoding A ⁇ peptide or A ⁇ polypeptides with and without linkers and/or cleavable linkers and with or without protein-based carriers can be joined as one contiguous nucleic acid, eg., within an expression vector.
• RNA nucleic acid can be RNA.
• RNA nucleic acid that encodes an immunogen and is used as a vaccine can be referred to as a "RNA immunogen” or "RNA vaccine” or “mRNA vaccine” as the encoded polypeptides are expressed in vivo after administration of the RNA.
• Ribonucleic acid (RNA) vaccines can safely direct a subject’s cellular machinery to produce one or more polypeptide(s) of interest.
• a RNA vaccine can be a non-replicating mRNA (messenger-RNA) or a vitally derived, self-amplifying RNA.
• mRNA-based vaccines encode the antigens of interest and contain 5' and 3' untranslated regions (UTRs), whereas self-amplifying RNAs encode not only the antigens, but also the viral replication machinery that enables intracellular RNA amplification and abundant protein expression
• In vitro transcribed mRNA can be produced from a linear DNA template using a T7, a T3 or an Sp6 phage RNA polymerase.
• the resulting product can contain an open reading frame that encodes the peptides of interest as disclosed herein, flanking 5'- and 3'-UTR sequences, a 5' cap and a poly(A) tail.
• a RNA vaccine can comprise trans-amplifying RNA (for example, see Beissert el al., Molecular Therapy January 202028(1 ): 119-128).
• RNA vaccines encode an A ⁇ peptide and a tau peptide as disclosed herein, and are capable of expressing the A ⁇ and a tau peptides, in particular if transferred into a cell such as an immature antigen presenting cell.
• RNA may also contain sequences which encode other polypeptide sequences such as immune stimulating elements.
• the RNA of a RNA vaccine can be modified RNA.
• modified in the context of the RNA can include any modification of RN A which is not naturally present in RNA.
• modified RNA can refer to RNA with a 5'-cap: however, RN A may comprise further modifications.
• a 5' ⁇ cap can be modified to possess the ability to stabilize RNA when attached thereto.
• a further modification may be an extension or truncation of the naturally occurring poly(A) tail or an alteration of the 5’- or 3' -untranslated regions (UTR).
• the RNA e.g. or mRNA vaccine is formulated in an effective amount to produce an antigen specific immune response in a subject.
• the RNA vaccine formulation is administered to a subject in order to stimulate the humoral and/or cellular immune system of the subject against the A ⁇ and tau antigens, and thus may further comprise one or more adjuvant(s), diluents, carriers, and/or excipients, and is applied to the subject in any suitable route in order to elicit a protective and/or therapeutic immune reaction against the A ⁇ and tau antigens.
• nucleic acids such as, e,g., generating mutations in sequences, sub-cloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature. See, Sambrook, ed., MOLECULAR CLONING; A LABORATORY M ANUAL (2ND ED.), Vols. 1 -3, Cold Spring Harbor Laboratory, (1989); CURRENT PRO TOCOLS IN MOLECULAR BIOLOG Y, Ausubei, ed.
• Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art . These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffitsion chromatography, various immunological methods, e.g. fluid or gel precipitin reactions, immunodiffirsion, immuno-electrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescence assays.
• analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), and hyperdiffitsion chromatography
• Southern analysis Northern analysis, dot-blot analysis, gel electrophoresis (e.g., SDS-PAGE), RT-PCR, quantitative PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.
• Each of the peptides and immunogens described herein can be presented in a pharmaceutical composition that is administered with pharmaceutically acceptable adjuvants and pharmaceutically acceptable excipients.
• the adjuvant increases the titer of induced antibodies and/or the binding affinity of induced antibodies relative to the situation if the peptide were used alone,
• a variety of adjuvants can be used in combina tion with an immunogen of t he. discl osure to elicit an immune response.
• Some adjuvants augment the intrinsic response to an immunogen without causing conformational changes in the immunogen that affect the qualitative form of the response.
• An adjuvant may be a natural compound, a modified version of or derivative of a natural compound, or a synthetic compound.
• Some adjuvants include aluminum salts, such as aluminum hydroxide and aluminum phosphate, 3 De-O-acylated monophosphoryi lipid A (MPL TM ) (see GB 2220211 (RIBI ImmunoChein Research foe., Hamilton, Montana, now part of Corixa).
• MPL refers to natural and synthetic versions of MPL Examples of synthetic versions include PHAD® 3D-PHAD® and 3D(6A)-PHAD® (Avanti Polar Lipids (Croda), Alabaster, Alabama).
• QS-21 is a triterpene gly coside or saponin isolated from the bark of the Quillaja
• QS-21 products include Stimulon®' (Antigenics, inc., New York, NY; now Agenus, Inc, Lexington, MA) and QS-21 Vaccine Adjuvant (Desert King, San Diego, CA).
• Stimulon®' Antigenics, inc., New York, NY; now Agenus, Inc, Lexington, MA
• QS-21 Vaccine Adjuvant Desert King, San Diego, CA.
• QS-21 has been disclosed, characterized, and evaluated in US 5,057,540, and US 8,034,348 the disclosures of which are herein incorporated by reference. Additionally, QS-21 has been evaluated in numerous clinical trials in various dosages.
• SHINGRIX contains 50 mcg of QS-21 In certain embodiments, the amount of QS-21 is from about. 10 ⁇ g to about 500 ⁇ g.
• TQL1055 is an analogue of QS-21 (Adjuvance Technologies, Lincoln, NE).
• the semi-synthetic TQL1055 has been characterized in comparison to QS-21 as having high purity, increased stability, decreased local tolerability, decreased systemic tolerability.
• TQL1055 has been disclosed, characterized, and evaluated in US20180327436A1, WO2018191598A1, W02018200656A1, and W02019079160A1, the disclosures of which are herein incorporated by reference.
• US20180327436A1 teaches that 2.5 fold more TQ1055 was superior to 20 ⁇ g QS-21 but there was not an improvement over 50 ⁇ g TQ1055.
• unlike QS-21 there was no increase in either weight loss or hemolysis of RBC as the TQL1055 dose increased.
• WO2018200656A1 teaches that with an optimal amount of TQ1055, one can lower the amount of antigen and achieve superior titers.
• the amount of TQL1055 is from about 10 ⁇ g to about 500 ⁇ g.
• adjuvants are oil in water emulsions (such as squalene or peanut oil), optionally in combination with immune stimulants, such as moriophosphoryl lipid A (see Stoute et al., N. Engl. J. Med. 336, 86-91 (1997)). plutonic polymers, and killed mycobacteria.
• Ribi adjuvants are oil-in-water emulsions. Ribi contains a metabolizable oil (squalene) emulsified with saline containing Tween 80. Ribi also contains refined mycobacterial products which act as immunostimulants and bacterial monophosphoryl lipid A.
• adjuvants can be CpG olioguucleotides (see WO 98/40100), cytokines (e.g,, IL-1 , IL-1 alpha and ⁇ peptides, IL-2, y- 1NF, IL- 10, GM-CSF), chemokines (e.g., MlP1- ⁇ and ⁇ , and RA'NTES), saponins, RNA, and/or TLR.
• agonists for example, TLR4 agonists such as MPL and synthetic MPL molecules
• Adjuvants can be administered as a component of a therapeutic composition with an active agent, or can be administered separately, before, concurrently with, or after administration of the therapeutic agent
• the adjuvant is QS-21 (StimuIori rM ').
• the adjuvant is MPL.
• the amount of MPL is from about 10 ⁇ g to about 500 ⁇ g.
• the adjuvant is TQL1055, In certain embodiments, the amount of TQL1055 is from about 10 ⁇ g to about 500 ⁇ g.
• the adjuvant is QS21. In certain embodiments, the amount of QS21 is from about 10 ⁇ g to about 500 ⁇ g..
• the adjuvant is a combination of MPL and QS-21 .
• the adjuvant is a combination of MPL and TQL1055.
• the adjuvant can be in a liposomal formulation.
• some embodiments of the disclosure can comprise a multiple antigen presenting system (MAP).
• MAP multiple antigen presenting system
• Multiple antigen-presenting peptide vaccine systems have been developed to avoid the adverse effects associated with conventional vaccines (i.e., live- attenuated, killed or inactivated pathogens), carrier proteins and cytotoxic adjuvants.
• Two main approaches have been used to develop multiple antigen presenting peptide vaccine systems; (1) the addition of functional components, e.
• T-cell epitopes g., T-cell epitopes, cell-penetrating peptides, and lipophilic rnoieties
• synthetic approaches using size-defined nanomaterials, e.g:, self- assembling peptides, non-peptidic dendrimers, and gold nanoparticles, as antigen-displaying platforms.
• Use of a multiple antigenic peptide (MAP) system can improve the sometimes poor immunogemcity of subunit peptide vaccines.
• the MAP comprises one or more of a Lys-based dendritic scaffold, helper T-cell epitopes, immune stimulating lipophilic rnoieties, cell penetrating peptides, radical induced polymerization, self-assembling nanoparticles as antigen- presenting platforms and gold nanoparticles.
• compositions for parenteral administration are preferably sterile and substantially isotonic and manufactured under GMP conditions.
• Pharmaceutical compositions can be provided in unit dosage form the dosage for a single administration).
• Pharmaceutical compositions can be formulated using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries. The formulation depends on the route of administration chosen.
• the peptides of the disclosure can be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank’s solution, Ringer’s solution, or physiological saline or acetate buffer (to reduce discomfort at the site of injection).
• the solution can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
• peptide compositions can be in lyophilized form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
• Peptides can also be administered in the form of a nucleic acid encoding the peptide(s) and expressed in situ in a subject.
• a nucleic acid segment encoding an immunogen is typically linked to regulatory elements, such as a promoter and enhancer that allow expression of the DMA segment in the intended target cells of a subject.
• regulatory elements such as a promoter and enhancer that allow expression of the DMA segment in the intended target cells of a subject.
• promoter and enhancer elements from, for example, light or heavy chain immunoglobulin genes or the CMV major intermediate early promoter and enhancer are suitable to direct expression.
• the linked regulatory' elements and coding sequences are often cloned into a vector.
• DNA and RNA can be delivered in naked form (r.e., without colloidal or encapsulating materials).
• viral vector systems can be used including retroviral systems (see, e.g., Boris ⁇ I..awrie and Teumin, Cur. Opin. Genet. Develop. 3, 102-109 ( 1993)); adenoviral vectors (see, e.g., Bett el al, J. Virol. 67(10), 591 1 ( 1993)); adeno-associated virus vectors (see, e.g., Zhou el al., J. Exp.
• viral vectors from the pox family including vaccinia virus and the avian pox viruses, viral vectors from the alpha virus genus such as those derived from Sindbis and Semliki Forest Viruses (see, e.g., Dubensky et al., J. Virol.
• Venezuelan equine encephalitis virus see US 5,643,576
• rhabdoviruses such as vesicular stomatitis virus (see WO 96/3462,5)and papillomaviruses (Ohe el al., Human Gene Therapy 6, 325-333 (1995); Woo el al., WO 94/12629 and Xiao & Brandsma, Nucleic Acids. Res. 24, 2620-2622 (1996)).
• DN A and RNA encoding an immunogen, or a vector containing the same can be packaged into liposomes, nanoparticles or lipoproteins complexes.
• suitable polymers include, for example, protamine liposomes, polysaccharide particles, cationic nanoemulsion, cationic polymer, cationic polymer liposome, cationic lipid nanoparticles, cationic lipid, cholesterol nanoparticles, cationic lipid-cholesteroi, PEG nanoparticle, or dendrimer nanoparticles.
• Vectors and DNA encoding an immunogen can also be adsorbed to or associated with particulate carriers, examples of which include polymethyl methacrylate polymers and polylactides and poly(lactide ⁇ co-glycolides), (see, e.g., McGee el al. , J. Micro Encap. 1997; 14(2).T97-210).
• Pharmaceutically acceptable carrier compositions can also include additives, including but not limited to water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymers, carboxymethylcellulose sodium, sodium polyacrylate, sodium alginate, water-soluble dextran, carboxymethyl starch sodium, pectin, methylcellulose, ethylcellulose, xanthan gum, gum arabic, casein, agar, polyethylene glycol, diglycerine, glycerine, propylene glycol, petrolatum, paraffin, stearyl alcohol, stearic acid, human serum albumin, mannitol, sorbitol, lactose, and surfactants acceptable as pharmaceutical additives.
• additives including but not limited to water, pharmaceutically acceptable organic solvents, collagen, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymers, carboxymethylcellulose sodium, sodium polyacrylate, sodium alginate, water-soluble dextran
• plaques has been found in several diseases including Alzheimer’s disease, Down’s syndrome, mild cognitive impairment, cerebral amyloid angiopathy, postencephalitic parkinsonism, postraumatic dementia or dementia pugihstica, Pick’s disease, type C Niemann-Pick disease, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, argyrophilic grain disease, amyotrophic lateral sclerosis/parkinsonism dementia complex of Guam, corticobasal degeneration (CBD), dementia with Lewy bodies, Lewy body variant of Alzheimer’s disease (LBVAD), chronic traumatic encephalopathy (CTE), Parkinson’s disease, progressive supranuclear palsy (PSP), dry age- related macular degeneration (AMD), and inclusion -body myositis,
• CBD corticobasal degeneration
• LVAD Lewy body variant of Alzheimer’s disease
• CTE chronic traumatic encephalopathy
• Parkinson’s disease progressive supran
• compositions and methods of the disclosure can be used in treatment or prophylaxis of any of these diseases. Because of the widespread association between neurological diseases and A ⁇ , the compositions and methods of the disclosure can be used in treatment or prophy laxis of any subject showing elevated levels of A ⁇ ) (e.g., in the CSF) compared with a mean value in individuals without neurological disease. The compositions and methods of the disclosure can also be used in treatment or prophy laxis of neurological disease in individuals having a mutation in A ⁇ associated with neurological disease. The methods are particularly suitable for treatment or prophylaxis of Alzheimer's disease.
• Subjects amenable to treatment include individuals at risk of disease but not showing symptoms, as well as patients presently showing symptoms, including treatment naive subjects that have not been previous treated for disease.
• Subjects at risk of disease include those in an aging population, asymptomatic subjects with A ⁇ pathologies and having a known genetic risk of disease. Such individuals include those having relatives who have experienced this disease, and those whose risk is determined by analysis of genetic or biochemical markers.
• Genetic markers of risk include mutations in A ⁇ , as well as mutations in other genes associated with neurological disease.
• the ApoE4 allele in heterozygous and even more so in homozygous form is associated with risk of Alzheimer’s disease (AD)
• Other markers of risk of Alzheimer’s disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 referred to as the Hardy and Swedish mutations respectively, mutations in the presenitin genes, PSI and PS2, a family history of AD, hypercholesterolemia or atherosclerosis.
• Individuals presently suffering from Alzheimer’s disease can be recognized by PET imaging, from c haracteristic dementia, as well as the presence o f ri sk factors described above.
• a number of diagnostic tests are available for identifying individuals who have AD. These include measurement of CSF or blood A ⁇ 42 levels. Decreased A ⁇ 42 levels can signify the presence of AD, as well as increased A ⁇ 40 and a reduced A ⁇ 42/A ⁇ 40 ratio.
• Some mutations associated with Parkinson’s disease for example, Ala30Pro or Ala53Thr, or mutations in other genes associated with Parkinson's disease such as leucine-rich repeat kinase ( LR.R.K2 or PARKS). Subjects can also be diagnosed with any of the neurological diseases mentioned above by the criteria of the DSM' IV TR.
• treatment can begin at any age (e.g., 10, 20, 30, or more). Usually, however, it is not necessary to begin treatment until a subject reaches 20, 30, 40, 50, 60, 70, 80 or 90 years of age. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying antibody levels over time. If the response falls, a booster dosage is indicated. In the case of potential Down ’s syndrome patients, treatment can begin antenatally by administering therapeutic agent to the mother or shortly after birth.
• the disclosure provides methods of inhibiting or reducing aggregation of A ⁇ in a subject having or at risk of developing Alzheimer’s disease.
• the methods include administering to the subject the compositions as disclosed herein.
• a therapeutically effective amount is a dosage that, when given for an effecti ve period of time, achieves the desired immunological or clinical effect.
• Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered at set intervals (e.g., weekly, monthly) or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
• compositions described herein can be used in methods for treating or effecting prophylaxis and/or prevention of Alzheimer's disease.
• the compositions as disclosed herein provide compositions for reducing A ⁇ in a subject and/or m the tissue of the subject.
• the compositions as disclosed herein provide compositions for reducing A ⁇ in the brain of a subject.
• the A ⁇ reduced by the compositions is the pathological form(s) of the A ⁇ (e.g. extracellular plaque deposits of the ⁇ -amyloid peptide ( A ⁇ ); neuritic amyloid plaques),
• pathological indicators of neurodegenerative disease and/or ⁇ - amyloidopathies are decreased by the immunotherapy compositions.
• compositions described herein can be administered to a subject susceptible to, or otherwise at risk of a disease (e.,g., Alzheimer’s disease) in a regimen (dose, frequency and route of administration) effective to reduce the risk, lessen the severity, or delay the onset of at least one sign or symptom of the disease.
• a regimen dose, frequency and route of administration
• the regimen is effective to inhibit or delay A ⁇ plaque formation, and/or inhibit or delay its toxic effects and/or inhibit/or delay development of behavioral deficits.
• compositions described herein are administered to a subject suspected ofi or a patient already suffering from a disease (e,g., Alzheimer’s disease) in a regimen (dose, frequency and route of administration) effective to ameliorate or at least inhibit further deterioration of at least one sign or symptom of the disease.
• a regimen dose, frequency and route of administration
• the regimen is preferably effective to reduce or at least inhibit further increase of levels of A ⁇ plaques associated toxicides and/orbehavioral deficits.
• a regimen is considered therapeutically or prophy lactically effective if an individual treated achieves an outcome more favorable than the mean outcome in a control population of comparable subjects not treated by methods of the invention, or if a more favorable outcome is demonstrated in treated subjects versus control subjects in a controlled clinical trial (e.g., a phase II, phase II/III or phase 111 trial) at the p ⁇ 0.05 or 0.01 or even 0.001 level.
• a controlled clinical trial e.g., a phase II, phase II/III or phase 111 trial
• Effective doses of vary depending on many different factors, such as means of administration, target site, physiological state of the patient, whether the patient is an ApoE carrier, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic.
• the effective amount is a total dose of 25 ⁇ g to 1000 ⁇ g, or 50 ⁇ g to 1000 ⁇ g. In some embodiments, the effective amount is a total dose of 100 ⁇ g. In some embodiments, the effective amount is a dose of 25 ⁇ g administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 100 ⁇ g administered to the subject a total of two times. In some embodiments, the effective amount is a dose of 400 ⁇ g administered to the subject a total of two times. In some embodiments, the effecti ve amount is a dose of 500 ⁇ g administered to the subject a total of two times. In some embodiments, a RNA (e,g., mRNA) vaccine is administered to a subject by intradermal, intramuscular injection, or by mtranasal admin isfration .
• a RNA (e,g., mRNA) vaccine is administered to a subject by intradermal, intramuscular injection, or by mtranas
• the amount of an agent for active immunotherapy varies from 1 to .1 ,000 micrograms ( ⁇ g), or from 0.1-500 ⁇ g, or from 10 to 500 ⁇ g, or from 50 to 250 ⁇ g per patient and can be from 1-100 or 1-10 ⁇ g per injection for human administration.
• the timing of injections can vary significantly from once a day, to once a week, to once a month, to once a year, to once a decade.
• a typical regimen consists of an immunization followed by booster injections at time intervals, such as 6 week intervals or two months.
• Another regimen consists of an immunization followed by one or more booster injections 1, 2, 3, 4, 5, 6, or 12 months later.
• Another regimen entails an injection every two months for life.
• booster injections can be on an irregular basis as indicated by monitoring of immune response.
• the frequency of administration may be once or more as long as the side effects are within a clinically acceptable range.
• compositions or methods as disclosed herein comprise administering to a subject a nucleic acid vaccine comprising one or more DNA or RNA polynucleotides having an open reading frame encoding a first peptide and a second peptide wherein a dosage of between 10 ⁇ g/kg and 400 ⁇ g /kg of the nucleic acid vaccine is administered to the subject.
• the dosage of the RNA polynucleoti de is 1-5 ⁇ g, 5-10 ⁇ g, 10-15 ⁇ g, 15-20 ⁇ g, 10-25 ⁇ g, 20-25 ⁇ g, 20-50 ⁇ g, 30-50 ⁇ g, 40-50 ⁇ g, 40-60 ⁇ g, 60-80 ⁇ g, 60- 100 ⁇ g, 50-100 ⁇ g, 80-120 ⁇ g, 40-120 ⁇ g, 40-150 ⁇ g, 50-150 ⁇ g, 50-200 ⁇ g, 80-200 ⁇ g, 100-200 ⁇ g, 120-250 ⁇ g, 150-250 ⁇ g, 180-280 ⁇ g, 200-300 ⁇ g, 50-300 ⁇ g, 80-300 ⁇ g, 100-300 ⁇ g, 40- 300 ⁇ g, 50-350 ⁇ g, 100-350 ⁇ g, 200-350 ⁇ g, 300-350 ⁇ g, 320-400 ⁇ g, 40-380 ⁇ g, 40-100 ⁇ g, 100-
• the nucleic acid is administered to the subject by intradermal or intramuscular injection. In some embodiments, the nucleic acid is administered to the subject on day zero. In some embodiments, a second dose of the nucleic acid is administered to the subject on day seven, or fourteen, or twenty one.
• the compositions described herein are preferably administered via a peripheral route (i.e. one in which the administered composition results in a robust immune response and/or the induced antibody population crosses the blood brain barrier to reach an intended site in the brain, spinal cord, or eye. For peripheral diseases, the induced antibodies leave the vasculature to reach the intended peripheral organs. Routes of administration include oral, subcutaneous, intranasal, intradermal, or intramuscular.
• Intramuscular administration and subcutaneous administration can be made at a single site or multiple sites. Intramuscular injection is most typically performed in the arm or leg muscles. In some methods, agents are injected directly into a particular tissue where deposits have accumulated.
• the number of dosages administered can be adjusted to result in a more robust immune response (for example, higher titers).
• Au effective amount of a DNA or RNA encoded immunogen can be between about 1 nanogram and about I gram per kilogram of body weight of the recipient, or about between about 0.1 ⁇ g/kg and about 10 mg/kg, or about between about I ⁇ g/kg and about 1 mg/kg.
• Dosage forms suitable for internal administration preferably contain (for the latter dose range) from about 0.1 ⁇ g to 100 ⁇ g of active ingredient per unit.
• the active ingredient may vary from 0.5 to 95% by weight based on the total weight of the composition.
• an effecti ve dose of dendri tic cells loaded with the antigen is between about 10 4 and 10 8 cells.
• the nucleic acid compositions may be administered in a convenient manner, injection by a convenient and effective route.
• Routes can include, but are not limited to, intradermal "gene gun” delivery or intramuscular injection.
• the modified dendritic cells are administered by subcutaneous, intravenous or intramuscular routes.
• Other possible routes include oral administration, intrathecal, inhalation, transdermal application, or rectal administration.
• the composition may be coated in a material to protect the compound from the action of enzymes, acids and other natural conditions which may inactivate the compound.
• a material to prevent its inactivation for example, an enzyme inhibitors of nucleases or proteases (e.g., pancreatic trypsin inhibitor, diisopropylfluorophosphate and trasylol) or in art appropriate carrier such as liposomes (including water-in-oil-in-water emulsions as well as conventional liposomes (Strejan et al., J. Neuroimmuaol 7:27, 1984).
• the immunotherapeutic compositions disclosed herein may also be used in combination with other treatments for diseases associated with the accumulation of A ⁇ , for example, anti-A ⁇ antibodies such as antibodies that specifically bind to any of the A ⁇ epitopes disclosed herein, aducanumab or any of the antibodies disclosed in, for example, U.S. Patent Publication 2010/202968 and U.S. Patent No.
• the patient receives passive immunotherapy prior to the active immunotherapy methods disclosed herein. In. other methods, the patient receives passive and acti ve immunotherapy during the same period of treatment. Alternatively, patients may receive active immunotherapy prior to passive immunotherapy.
• Combinations may also include small molecule therapies and non- immunogenic therapies such as RAZADYNE ® (galantamine), EXELON ⁇ (rivastigmine), and ARICEPT® (donepezil) and other compositions that improve the fimction of nerve cells in the brain.
• RAZADYNE ® galantamine
• EXELON ⁇ rivastigmine
• ARICEPT® donepezil
• compositions of the disclosure may be used in the manufecture of medicaments for the treatment regimens described herein.
• Desired outcomes of the methods of treatment as disclosed herein vary according to the disease and patient profile and are determinable to those skilled in the art. Desired outcomes include an improvement in the patient’s health status. Generally, desired outcomes include measurable indices such as reduction or clearance of pathologic amy loid fibrils, decreased or inhibited amyloid aggregation and/or deposition of amy loid fibrils, and increased immune response to pathologic and/or aggregated amyloid fibrils. Desired outcomes also include amelioration of amyloid disease-specific symptoms.
• relative terms such as “improve,” “increase, *' or “reduce*' indicate values relative to a control, such as a measurement in the same individual prior to initiation of treatment described herein, or a measurement in a control individual or group.
• a control individual is an individual afflicted with the same amyloid disease as the individual being treated, who is about the same age as the individual being treated (to ensure that the stages of the disease in the treated individual and the control individual are comparable) but who has not received treatment using the disclosed formulations.
• a control individual is a healthy individual, who is about the same age as the individual being treated. Changes or improvements in response to therapy are generally statistically significant and described by a p- value less than or equal to 0.1 , less than 0.05, less than 0.01 , less than 0.005, or less than 0.001 may be regarded as significant.
• Effective doses of the compositions as disclosed herein, for the treatment of a subject vary depending upon many different factors, including means of administration, target site, physiological state of the patient, whether the patient is human or an animal, other medications administered, if any, and whether treatment is prophylactic or therapeutic.
• Treatment dosages can be titrated to optimize safety and efficacy.
• the amount of immunogen can also depend on whether adjuvant is also administered, with higher dosages being required in the absence of adjuvant.
• the amount of an immunogen for administration sometimes varies from 1-500 ⁇ g per patient and more usually from 5-500 ⁇ g per injection for human administration. Occasionally, a higher dose of 1-2 mg per dosage is used. Typically, about 10, 20, 50 or 100 ⁇ g is used for each human dosage.
• the timing of dosages can vary significantly from once a day, to once a year, to once a decade.
• the dosage is greater than 1 ⁇ g/patient and usually greater than 10 ⁇ g/patient if adjuvant is also administered, and greater than 10 ⁇ g/patient and usually greater than 100 ⁇ g/patient in the absence of adjuvant.
• a typical regimen consists of an immunization followed by booster dosage(s) at 6-week intervals.
• Another regimen consists of an immunization followed by booster dosage(s) 1, 2, 3, 4, 5, 6, or 12 months later.
• Another regimen entails dosage(s) every two months for life.
• booster dosage(s) can be on an irregular basis as indicated by monitoring of immune response.
• the second treatment can be administered according the product label or as necessary in view of the treatment with the compositions of the disclosure.
• a second treatment for Alzheimer’s disease such as, Razadyne® (galantamine), Exelon® (rivastigmine), and Aricept® (donepezil)
• the second treatment can be administered according the product label or as necessary in view of the treatment with the compositions of the disclosure.
• kits comprising the compositions disclosed herein and related materials, such as instructions for use (e.g.,package insert).
• the .instructions for use may con tain, for example, instructions for administration of the compositions and optionally one or more additional agents.
• Tire containers of peptide and/or nucleic acid compositions may be unit doses, bulk packages (e.g., multi-dose packages), or sub-unit doses.
• Kits can also include a second container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer’s solution and dextrose solution. It can also include other materials desirable from a commercial and user standpoint,, including other buffers, diluents, filters, needles, and syringes.
• BWFI bacteriostatic water for injection
• Each of the peptides, polypeptides, immunogens, and pharmaceutical compositions described herein may be for use in treating one or more of the diseases as described herein.
• each of the peptides, polypeptides, immunogens, and pharmaceutical compositions described herein may be for use in methods for treating one or more of the diseases as described herein.
• Each of the peptides, polypeptides, immunogens, and pharmaceutical compositions described herein may be used in a method for manufacturing a medicament for treating or use in treating one or more of the diseases as described herein.
• Test article was prepared by combining 25 ⁇ g of test immunogen and 25 ⁇ g of QS21. adjuvant in 200 ⁇ l phosphate buffered saline (PBS). Mice were bled on day 21, 49 and 77 by nicking tails and collecting 50 ⁇ l of blood, followed by processing to serum.
• the peptides tested included AEFRHDSGC (SEQ ID NO:38) and DAEFRHDC (SEQ ID NO:39).
• Immunogens contained one A ⁇ peptide, a C-terminal linker and a C-terminal cysteine and were coupled through the C-terminal cysteine to CRM-197 with a maleimide linkage.
• Guinea pigs were injected intramuscularly with 50 ⁇ g of a test immunogen, 25 ⁇ g QS21 in 200 ⁇ l of Addavax on day 0, 21, 49 and 77. Bleeds were done 7 days post immunization.
• the peptides tested included DAEFRHDC (SEQ ID NO:39) and QKLVFFAEC (SEQ ID NO:40).
• Immunogens again contained one A ⁇ l peptide, a C-terminal linker, and a C- terminal cysteine and were coupled through the C-terminal cysteineto CRM-197 with a maleimide linkage.
• T he immunogen concentration was 0.5 mg/ml. Prior to each administration of the test immunogen., approximately a 3 cm 3 area on each hind limb was shaved and wiped with ethanol for visualization of the injection site. Each animal, received a test immunogen dose of 200 microliters (0.25 micrograms/microliter) divided into two separate sites each of 100 microliter per injection (i.e., animals received 50 ⁇ g of immunogen in 100 ⁇ l PBS + 25 ⁇ g of QS-21 in 100 pi Addavax). A 25G-27G needle was inserted intramuscularly into the hind limb, approximately 0,25 - 0.5 cm deep, and injected at 100 microliters per site. Injection sites were rotated each administration between four separate sites per hind limb and separated by at least 2 cm. [00120] Example 2: Measurement of Antibody Titers
• a ⁇ 1 -15 and A ⁇ 1 -28 were both used at different parts of the study. Both of these will not form aggregates.
• 2 ⁇ g/ml A-beta monomers were coated at coated on to the plate 100 ⁇ l per well in PBS and incubated overnight at room temperature. Plates were blocked for 1 hour with 1% BSA in PBS. Plates were aspirated and to row A 200 ⁇ l of 0.1% BSA in PBS Tween was added. In column 1 negative Guinea pig serum was added at 1/100 dilution while the rest of the row contained 1/100 test serums. Rows were serially diluted by 50% per step down the plate giving dilution range of 1/100 to 1/12800.
• a 1/5000 dilution of anti- mouse IgG HRP in 0.1 % BSA in PBS Tween was prepared and then 100 ⁇ l added to the washed well.
• the reaction mixture was incubated for 1 hour and was washed, OPD substrate was prepared using ThermoFisher OPD tablets at I tablet per 10 mis.
• ThermoFisher substrate buffer was added at 1/10 dilution and each well received 100 ⁇ l and was incubated for 15 minutes.
• 50 ⁇ l of 2N H 2 SO 4 was added to stop the reaction and plates were read at 490 mn on a Molecular Devices Spectromax. Titer was defined as the dilution giving 50% maximum OD measurement and was extrapolated if ft fell between dilutions.
• Antibody titers in mice immunized with A ⁇ epitopes were immunized with A ⁇ epitopes.
• Example 3 Staining of Alzheimer's brain tissue with sera from Guinea pigs immunized with a vaccine as disclosed herein.
• the peptide may comprise, consist, or consist essentially of the recited sequences.
• incorporated in this disclosure are the -following sequences that can be part of the compositions comprising, consisting of or consisting essentially of an arnyioid-beta (A ⁇ ) peptide as disclosed herein.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Toxicology (AREA)
• Peptides Or Proteins (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Priority Applications (9)

Applications Claiming Priority (2)

Publications (1)

Family

ID=80776325

Family Applications (1)

Country Status (12)

Cited By (6)

Citations (3)

Family Cites Families (4)

• 2021
  • 2021-05-19 US US18/245,523 patent/US20230364210A1/en active Pending
  • 2021-05-19 TW TW110118154A patent/TW202212348A/zh unknown
  • 2021-05-19 AR ARP210101370A patent/AR122127A1/es unknown
  • 2021-05-19 CA CA3192383A patent/CA3192383A1/en active Pending
  • 2021-05-19 JP JP2023517697A patent/JP2023541669A/ja active Pending
  • 2021-05-19 AU AU2021345451A patent/AU2021345451A1/en active Pending
  • 2021-05-19 EP EP21869919.7A patent/EP4213942A4/en active Pending
  • 2021-05-19 CN CN202180063988.4A patent/CN116724046A/zh active Pending
  • 2021-05-19 MX MX2023003009A patent/MX2023003009A/es unknown
  • 2021-05-19 WO PCT/US2021/033180 patent/WO2022060424A1/en not_active Ceased
  • 2021-05-19 IL IL301223A patent/IL301223A/en unknown
  • 2021-05-19 KR KR1020237012808A patent/KR20230087495A/ko active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events